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Abstract
Background: As there are different views on the effects of aminophylline on neonatal renal function, we intended to observe the 
effects of aminophylline on renal dysfunction in neonates with prenatal asphyxia.
Methods: This randomized trial was conducted in the Obstetrics and Gynecology Hospital, Tehran, Iran, from June 2016 to May 
2017, in neonates with moderate to severe asphyxia during birth. Fifty-six neonates were divided randomly into two groups. The 
intervention group received one dose of 5mg/kg slow intravenous aminophylline injection and the placebo group received 2 
mL/kg of intravenous 10% solution of dextrose saline during the first hour of life. They were monitored and compared for renal 
functional indices, electrolytes, and complications of asphyxia during the three days of life. 
Results: The mean of Cr (37.9 ± 8.8 vs 38.5 ± 9.4 and 20.8 ± 4.8 vs 30.1 ± 5.2 μmol/L), GFR (21.55 ± 4.7 vs 20.25 ± 4.4 and 30.8 
± 7.1 vs 20.1 ± 6.5 mL/minute/1.73 m2), Na (135.1 ± 12.4 vs134.5 ± 11.2 and 128.9 ± 11.5 vs 134.2 ± 10.9 mEq/L), and urine 
output (98.2 ± 25 vs 96.8 ± 23 and 148.7 ± 35 vs 108.8 ± 20 cc) were in the aminophylline treated and placebo group on the 1st  
and 3rd days, respectively. The mean difference of Cr (-9.3 (-8.9; -9.7) μmol/L); (P = 0.02), GFR (10.7 (10.1; 11.3) mL/minute/1.73 
m2) (P = 0.009), Na (-5.3 (-5.9; -4.7) mEq/L) (P = 0.002), and urine volume (39.9 (24.9; 54.9) cc) (P = 0.001) presented statistically 
significant differences on the third day between the intervention and placebo group. 
Conclusion: Aminophylline was effective in preventing renal dysfunction  in neonates with asphyxia. Neonates who received 
aminophylline indicated a significant improvement in GFR and urine output on the first day of life.
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Perinatal asphyxia is a more prominent issue in developing 
countries, resulting from lack of prepartum care and 
advanced natal care with a prevalence reported up to 5%.1 
Neonates with perinatal asphyxia are 82% likely to have 
organ dysfunction in one or more of their organs, including 
the brain (72%), kidneys (42%) and lungs (26%).2 
Kidneys are the second most affected organs in perinatal 
asphyxia,3 with the incidence rates of acute kidney injury, 
functional renal failure, and intrinsic renal failure reported 
at 12%, 48.14%, and 51.85%, respectively.4
Perinatal asphyxia is perceived to be the primary cause of 
transient renal dysfunction or acute renal failure.5 Kidney 
malfunction manifests as oliguria and acute renal failure, 
which is caused by acute tubular necrosis.6
Furthermore, renal vein or artery thrombosis can occur 
along with severe perinatal asphyxia.7 The prognosis of 
renal dysfunction is of utter importance in preventing 
complications like hyponatremia caused by increased fluid 
load and hyperkalemia.3
If asphyxia is severe, first peripheral tissues (like muscle 
tissue and the heart), and brain tissue will be deprived 
of oxygen, which in turn, will result in a shift towards 
anaerobic glycolysis.8 Anaerobic glycolysis will produce 
lactic acid, which causes metabolic acidosis and adenosine 
triphosphate hydrolysis. In addition, there will be an 
increase in adenosine.9 Adenosine acts as an inhibitory 
neuro-regulator in the central nervous system in pathways 
of respiratory neural inhibition during hypoxia.10 In the 
kidneys, in hypoxemic states, adenosine causes dilation 
of the efferent arteriole, therefore lowering the effective 
filtration pressure and glomerular filtration rate (GFR).11
The major role of adenosine in mediating renal 
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that administering theophylline, which is a nonspecific 
antagonist of adenosine cell surface receptors, could 
prevent the hypoxemia-induced decrease in GFR.12
Although some studies do not support theophylline’s 
positive effects on the renal function of neonates with 
perinatal asphyxia, many other studies suggest multiple 
beneficial effects of theophylline in this context, through 
clinical trials.13
As there are opposing views on this subject matter, and 
lack of as many studies done on aminophylline to prove 
its positive effects on complications of perinatal asphyxia, 
we intend to study the effects of aminophylline on renal 
function of neonates with severe perinatal asphyxia in 
comparison to newborns not receiving the medication, 
through a clinical trial.
Materials and Methods
Design and Patients
This is a double-blinded randomized clinical trial 
conducted in Shahid Akbarabadi hospital affiliated to Iran 
University of Medical Sciences, Tehran, Iran, from June 
2016 to May 2017 to evaluate the effect of aminophylline 
injection in the first hours of life on renal function in 
neonates with perinatal asphyxia. A randomized blocking 
(block size of four) method was applied using a computer-
generated random number list prepared by an investigator 
with no clinical involvement in the trial. Sixty-two term 
neonates who were born with moderate to severe asphyxia 
during birth were assessed for eligibility. The severity of 
asphyxia was categorized as severe (Apgar score: 1–3) 
or moderate (Apgar score: 4–6). Eligible neonates were 
divided randomly using random blocks into two groups of 
twenty-eight. We excluded neonates if they had congenital 
anomalies, history of maternal drugs causing neonatal 
depression, blood culture-positive sepsis, or if the neonates 
required a mechanical mode of ventilation (Figure 1). 
Blinding and Intervention
This study was conducted double-blinded: the patients 
(neonates) and the evaluator (analyzer) were not aware of 
the course of the intervention. The researcher and clinicians 
were informed of the allocation in the intervention group. 
The intervention group received one dose of 5 mg/kg 
(2 mL) slow intravenous aminophylline injection over 5 
minutes during the first hour of life. The placebo group 
received 2 milliliters of intravenous 10% solution of 
dextrose saline as placebo under the same conditions as 
the intervention group.
Outcomes and Measurements
In this study renal function was defined as the primary 


































Assessed for eligibility (n=62) 
Excluded (n= 6) 
   Not meeting inclusion criteria 
(n=3) 
   Declined to participate (n=3) 
Analyzed (n= 25)  
 
• Two neonates died in first two days. 
• One neonate excluded because of 
parental unwillingness to continue 
cooperation 
 
Allocated to intervention (n=28) 
 
Received allocated intervention (n=28) 
 
Three neonates died in first three 
days. 
 
Allocated to control (n=28) 
 
 Received allocated placebo (n=28  ) 
 







Figure 1. Follow-up Diagram of Patients (According to Consort Statement).
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(BUN, mg/dL), creatinine (Cr, μmol/L), GFR [GFR was 
estimated on alternate days using Schwartz’s formula: GFR 
(mL/min/1.73 m2) = 0.45 × length (cm)/plasma creatinine 
(mg/100 mL)], sodium (Na, mEq/L), potassium (K, 
mEq/L), calcium (Ca, mg/dL) and the neonates’ fluid 
intake and urine output (cc) on 1st and 3rd days were 
monitored. 
Secondary outcomes were comparison of renal function 
on 3rd day between severe and moderate asphyxia 
and complications of prenatal asphyxia between the 
aminophylline-treated and placebo groups. 
Data Collection Methods
The data were collected by clinical observation, medical 
history, and laboratory findings; all were gathered in 
checklists and then recorded in the data bank. 
Data Analysis
The sample size of the study was calculated at 28 for each 
group, based on an expected standardized mean difference 
of aminophylline effect on continuous subjective outcome 
of 1.1,14 and considering study power of 80% and two-
sided alpha error of 0.05. The data was entered into the 
statistical analysis software, SPSS, version 16, and then 
statistically analyzed. Kolmogorov-Smirnov was used to 
assess the normality of data distribution. All descriptive 
data had normal distribution. Therefore, the results for 
the quantitative variables were reported in mean ± SD 
format and the ordinal qualitative variables were reported 
in frequency and percentages. For comparing quantitative 
and qualitative variables, the Mann-Whitney U, Student’s 




A total number of 56 neonates met the inclusion criteria 
of perinatal asphyxia: these neonates were divided into 
two groups (aminophylline and placebo groups). Twenty-
eight neonates were enrolled in each group. Of 56 eligible 
neonates in the aminophylline and placebo groups, 3 
neonates were excluded from each group. Ultimately, 
the analysis was done with 25 neonates in each group 
(Figure 1). 
Each group received either aminophylline or an equal 
volume of placebo at similar chronological ages. The 
minimum, maximum and mean of gestational age were 
37, 42 and 39.3 ± 4.8 weeks, respectively. The minimum, 
maximum and mean of birth weight was 1950, 4200 and 
3105 ± 940 g. The mean values of first- and fifth-minute 
Apgar score were 2.24 ± 2.3 and 5.4 ± 2, respectively and 
54% of the neonates presented with moderate prenatal 
asphyxia. The demographic and clinical characteristics of 
the studied asphyxiated neonates are presented in Table 1.
According to the results, differences in gender, gestational 
age, birth weight, mode of delivery (NVD, C/S), Apgar 
score, severe and moderate asphyxia were not significant 
between the two groups of aminophylline and placebo 
treatment (Table 1).
The comparison of BUN, Cr, GFR, Na, K, Ca, and 
urine output between aminophylline and placebo groups 
at baseline and third day is presented in Table 2. BUN, Cr, 
GFR, Na, and K did not follow the normal distribution 
pattern; therefore, Mann-Whitney U test  was used for 
comparison. According to the results, both groups had 
similar daily estimated BUN, K, and Ca. There was no 
difference in the change in BUN, K, and Ca from baseline 
to 72 hours between the groups (P > 0.05). 
Urine creatinine during the first three days of life 
showed a non-significant difference between the two 
groups. There was a significant difference in the change 
in creatinine from baseline to 72 hours between the 
groups (P = 0.022). GFR, as calculated using the Schwartz 
formula, showed a statistically non-significant difference 
between the two groups on the first day, which later 
became highly statistically significant (P < 0.009) between 
the aminophylline and placebo groups (30.8 ± 7.1 vs. 20.1 
Table 1. Demographic and Clinical Characteristics of Aminophylline and Placebo Groups
Variable Aminophylline Group (n = 25) Placebo Group (n = 25) P Value
Gender, No. (%)
Male 14 (56) 17 (68)
0.156*
Female 11 (44) 8 (32)
Gestational age, wk 
Min-Max 37–42 38–41
0.085**




Mean ± SD 3050 ± 960 3160 ± 970
Delivery mode, No. (%)
NVD 16 (64) 13 (52)
0.298*








Moderate 13 (52) 14 (56)
0.652*
Severe 12 (48) 11 (44)
SD; standard deviation, NVD; normal vaginal delivery, C/S; cesarean section.
*Chi-square test; **Student’s t test.
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± 6.5 mL/min/1.73 m2) on the 3rd day. The level of Na 
showed a statistically non-significant difference between 
the two groups on the first day, which became statistically 
significant between the two groups on the 3rd day (P = 
0.002). Both groups exhibited an increase in urine output 
on the 3rd day, which was significantly higher in the 
aminophylline group than the placebo group (P = 0.001). 
Comparison of renal function between severe and 
moderate asphyxia in neonates was considered as one of 
the secondary outcomes in this study. According to the 
results, there was a significant difference in the value of 
Na between neonates with severe and moderate asphyxia 
(P = 0.042). Also, the mean third day urine volume in 
the aminophylline group significantly different between 
severe and moderate asphyxia (P = 0.035) (Table 3). Table 
3 depicts the results of comparison of renal function on 
the 3rd day between severe and moderate asphyxia in 
neonates. 
Five deaths occurred during the study period (two deaths 
in the aminophylline and three deaths in the placebo 
group) but the difference between the groups was not 
significant (P > 0.05). The occurrence of complications 
was reported in numbers and percentage. Complications 
of prenatal asphyxia in this study consisted of pulmonary 
dysfunction, convulsion, cerebral hemorrhage, and death. 
According to the results, the complications of asphyxia 
were not significantly different between the two groups 
(Table 4, Figure 2).
Discussion
Given that asphyxia is the main cause for acute or transient 
kidney failure,15 this study was designed to assess the 
effects of aminophylline on renal dysfunction in neonates 
with prenatal asphyxia. The obtained results indicate that 
on the 3rd day, serum Cr, GFR levels, Na value and urine 
output of the neonates receiving aminophylline treatment 
was statistically different compared to the group receiving 
placebo. In contrast, no significant difference was observed 
between the two groups in all variables on the first day and 
BUN, K, Ca values on the third day. 
Data from the aminophylline treated group revealed a 
significant decrease in serum creatinine levels on the 3rd 
day. The result of a study by Eslami et al showed that the 
level of serum creatinine was not significantly different 
between the theophylline and control groups on the 
first day. However, these levels significantly decreased in 





PAminophylline Group (n = 25) Placebo Group (n = 25)
Lower Upper
Mean ±SD Mean ±SD
BUN
 First day 24.6 ± 4.0 25.1 ± 4.2 -0.5 -0.3 -0.7 0.308*
Third day 23.4 ± 6.2 27.6 ± 5.8 -4.2 -4.6 -3.8 0.052*
Cr
 First day 38.5 ± 9.4 37.9 ± 8.8 -0.6 -0.1 -1.2 0.652*
Third day 20.8 ± 4.8 30.1 ± 5.2 -9.3 -8.9 -9.7 0.022*
GFR
First day 21.55 ± 4.7 20.25 ± 4.4 1.3 1 1.6 0.059*
Third day 30.8 ± 7.1 20.1 ± 6.5 10.7 10.1 11.3 0.009*
Na 
First day 135.1 ± 12.4 134.5 ± 11.2 0.6 -0.6 1.8 0.765*
Third day 128.9 ± 11.5 134.2 ± 10.9 -5.3 -5.9 -4.7 0.002*
K 
First day 4.9 ± 0.9 4.4 ± 2 0.5 1.8 -0.6 0.876*
Third day 4.5 ± 1.6 4.8 ± 1.9 -0.3 0 -0.6 0.446*
Ca
First day 8.5 ± 1.8 8.9 ± 1.7 -0.4 -0.5 -0.3 0.562**
Third day 8.7 ± 2.7 9.1 ± 2.2 -0.4 -0.9 0.1 0.438**
Urine 
output
First day 98.2 ± 25 96.8 ± 23 1.4 0.2 3.4 0.321**
Third day 148.7 ± 35 108.8 ± 20 39.9 24.9 54.9 0.001**
* Mann-Whitney U test; **Student t test.





PModerate (n = 27) Severe (n = 23)
Lower UpperMean ± SD Mean ± SD
BUN 23.6 ± 6.4 27.6 ± 5.9 -4.03 -4.53 -3.4 0.340*
K 5.1 ± 2.7 4.4 ± 1.9 0.7 0 1.1 0.984*
Ca 8.8 ± 3.6 8.6 ± 2.4 0.2 -0.2 0.4 0.636**
Cr 23.7 ± 4.2 27.5 ± 6.9 -3.8 -4.6 -7.4 0.346*
GFR 27.6 ± 7.8 22.9 ± 5.1 4.7 2 7.4 0.255*
Na 135.7 ± 12.3 127 ± 11.5 8.7 6 9.5 0.042*
Urine output 141.1 ± 29 114.2 ± 26 26.9 23.9 29.9 0.035**
* Mann-Whitney U test; **Student t test.
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the neonates of the theophylline group and significantly 
increased in the controls on the third day, which is similar 
to our findings.15
The estimated GFR increased significantly in the 
aminophylline treated group from 21.55 ± 4.7 on the 
1st day to 30.8 ± 7.1 mL/min/1.73 m2 on the 3rd day, 
indicating a significant difference compared to the control 
group. Studies by Youssef et al and Raina et al reported 
an increase in GFR in theophylline group compared to 
placebo group on the third day.16,17 
The findings of this study showed that neonates in 
the intervention group manifested a significant decrease 
in serum sodium levels after taking a loading dose of 
aminophylline. This effect of aminophylline has the 
potential to induce hyponatremia in critically ill neonates.18 
The general mechanisms for hyponatremia (defined as 
serum sodium <130 mmol/L) include the inability to 
excrete a given water load leading to volume overload and 
dilution of serum sodium levels, excessive gastrointestinal 
or renal sodium losses, and inadequate sodium intake.18,19 
The observation of the effect of aminophylline on serum 
sodium in asphyxiated neonates is in line with the 
findings of other authors.20,21 Pretzlaff et al found that an 
aminophylline bolus of 6 mg/kg given to eight children 
aged 1 month to 6 years already receiving a continuous 
infusion of furosemide increased urine output by over 
80% and increased sodium excretion; these variables 
returned to baseline by 6 hours.21 These results suggest that 
neonates on aminophylline could actually benefit from 
supplements of sodium ions, and that close monitoring is 
still needed to prevent any side effects. Nevertheless, based 
on the result of studies, aminophylline is suggested to be 
used in neonates in developing countries due to either lack 
of availability or cost of others drugs.18,22-24 
Table 4. Comparison of Complications of Prenatal Asphyxia between the Aminophylline and Placebo Groups on the Third Day
Variables Aminophylline Group (n = 25) Placebo Group (n = 25) P Value*
Pulmonary dysfunction, No. (%) 1(4) 1(4) 0.356
Convulsion, No. (%) 2(8) 1(4) 0.068

















With complication Without complication Total
Figure 2. Comparison of Complications between the Aminophylline and 
Placebo Groups.
The aminophylline group exhibited a significant 
increase in urine output during the first three days; there 
was a 0.68 mL/kg/h increase in urine output in the 
aminophylline group, and a 0.15.87 mL/kg/h increase in 
the placebo group. In line with our findings, in a study by 
Tamburro et al, the median urine output increased from 
3.5 [IQR: 2.0, 5.0] at baseline to 4.2 [IQR: 2.7, 5.6] at 
24-h with a median increase of 1.0 mL/kg/h ([IQR: −0.1, 
1.5] in the aminophylline group.14 Bell et al reported 
a small case series of 10 critically ill children who had a 
significant increase in urine output with theophylline 
administration.25 Aminophylline has been used in various 
dosages for treatment or prevention of renal dysfunction 
or diuresis in neonates.13-18,21-25 These applications have 
been stimulated by a growing understanding of the role of 
adenosine in neonatal renal physiology,26,27 and supported 
by animal studies examining renal effects of theophylline 
and other methylxanthines.28-30 Experiments in laboratory 
animals show that adenosine could act as a vasoconstrictive 
metabolite in the kidneys. Adenosine is produced and 
released during hypoxia and ischemia from the kidneys, 
causing a drop in GFR and filtration fraction.31,32 The 
non-specific antagonist of an adenosine receptor, such as 
theophylline, can prevent the vasoconstriction caused by 
it.33 It has been shown in animal models that adenosine 
antagonists can increase renal blood flow.34 In some 
studies using different low-dose theophylline regimens to 
prevent renal dysfunction following perinatal asphyxia, 
a marked reduction was observed in renal involvement, 
typically from 55% to 60% of controls to 17% to 25% of 
theophylline-treated patients.35-37 
In the present study, Na levels in neonates with severe 
asphyxia were significantly lower compared to the ones 
with the moderate form of the condition. In tandem 
with these findings, in a study by Thakur, a significant 
correlation was reported between serum sodium and Apgar 
score at 5 minutes.20 Basu et al found increased severity of 
hyponatremia with increased severity of birth asphyxia.38 
Also, Gopal concluded that oliguria, hyponatremia and 
abnormal sonographic findings are prognostic factors for 
renal failure in neonates with prenatal asphyxia during 
birth.8 Hyponatremia may occur in neonates with perinatal 
asphyxia as there is increased secretion of anti-diuretic 
hormone in neonates which leads to increased water 
retention and hence, dilutional hyponatremia.20 Another 
reason for hyponatremia is that the capacity of sodium 
reabsorption is limited and if the load of sodium reaching 
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the collecting tubules increases significantly, reabsorption 
does not occur proportionately and the sodium load is 
excreted in the urine.39 Another factor contributing to 
hyponatremia is partial resistance to aldosterone.40
Furthermore, the finding shows that the neonates’ urine 
volume on the third day has a statistically significant 
negative association with the severity of prenatal asphyxia. 
It seems that urine measurements soon after birth may be 
a tool to identify severity of neonatal asphyxia.41 
In summary, aminophylline prevented renal dysfunction 
in neonates with asphyxia. Neonates in the aminophylline 
group indicated a significant improvement in GFR and 
urine output on the first day of life. We suggest further 
studies on this topic, with larger sample sizes and longer, 
follow-up periods in our country so that the results would 
be qualitatively and quantitatively comparable to our 
study.
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